Resource Type

Journal Article 5

Year

2019 1

2017 1

2015 2

2012 1

Keywords

imatinib 4

chronic myeloid leukemia 2

dasatinib 2

CALLG2008 1

Philadelphia chromosome 1

acute lymphoblastic leukemia 1

allogeneic hematopoietic stem cell transplantation 1

chronic myeloid leukemia (CML) 1

complete cytogenetic response 1

gastrointestinal stromal tumour 1

hemoperitoneum 1

long-term follow-up 1

nilotinib 1

small bowel GIST 1

small bowel neoplasm 1

tyrosine kinase inhibitor 1

open ︾

Search scope:

排序: Display mode:

Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era

Haiyan He, Yang Shen, Yongmei Zhu, Saijuan Chen

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 204-211 doi: 10.1007/s11684-012-0202-x

Abstract: in three clinical phases, namely, chronic (CP), accelerated (AP), and blast (BP) phases, receiving imatinibA total of 275 CML patients (CP, 210; AP, 24; and BP, 41) who received imatinib between February 2001In CP patients, univariate analysis revealed that early treatment with imatinib, achieving CCyR within

Keywords: imatinib     chronic myeloid leukemia     complete cytogenetic response    

Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed

Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin

Frontiers of Medicine 2017, Volume 11, Issue 2,   Pages 229-238 doi: 10.1007/s11684-017-0506-y

Abstract: analyzed 153 newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive ALL enrolled into imatinibAll these results suggested that imatinib plus CALLG2008 was an effective protocol for Ph-positive ALL

Keywords: Philadelphia chromosome     acute lymphoblastic leukemia     imatinib     CALLG2008    

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Frontiers of Medicine 2019, Volume 13, Issue 3,   Pages 344-353 doi: 10.1007/s11684-018-0639-7

Abstract: Dasatinib is a highly effective second-generation tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML). In 2007, a pivotal phase-2 study of dasatinib as second-line treatment was initiated in 140 Chinese CML patients. This report from the 4-year follow-up revealed that 73% of 59 patients in chronic phase (CML-CP) and 32% of 25 patients in accelerated phase (CML-AP) remained under treatment. The initial dosage of dasatinib for CML-CP and CML-AP patients were 100 mg once daily and 70 mg twice daily (total= 140 mg/day), respectively. The cumulative major cytogenetic response (MCyR) rate among patients with CML-CP was 66.1% (versus 50.8% at 18 months), and the median time to MCyR was 12.7 weeks. All CML-CP patients who achieved MCyR after a 4-year follow-up also achieved a complete cytogenetic response. The cumulative complete hematological response (CHR) rate among patients with CML-AP was 64% (16/25), with three CML-AP patients achieving CHR between 18 months and 4 years of follow-up; the median time to CHR was 16.4 weeks. The adverse event (AE) profile of dasatinib at 4 years was similar to that at 6 and 18 months. The most frequently reported AEs (any grade) included pleural effusion, headache, and myelosuppression. These long-term follow-up data continue to support dasatinib as a second-line treatment for Chinese patients with CML.

Keywords: chronic myeloid leukemia (CML)     dasatinib     tyrosine kinase inhibitor     long-term follow-up    

A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Eric C.H. Lai,Kam Man Chung,Stephanie H.Y. Lau,Wan Yee Lau

Frontiers of Medicine 2015, Volume 9, Issue 1,   Pages 108-111 doi: 10.1007/s11684-014-0344-0

Abstract: A high dose imatinib was prescribed.

Keywords: gastrointestinal stromal tumour     hemoperitoneum     small bowel GIST     small bowel neoplasm     imatinib    

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Frontiers of Medicine 2015, Volume 9, Issue 3,   Pages 304-311 doi: 10.1007/s11684-015-0400-4

Abstract:

In the tyrosine kinase inhibitor (TKI) era, imatinib is the first-line therapy for patients with chronicappropriate treatment regimens for patients with disease that progressed to accelerated phase following imatinib

Keywords: chronic myeloid leukemia     imatinib     dasatinib     nilotinib     allogeneic hematopoietic stem cell transplantation    

Title Author Date Type Operation

Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era

Haiyan He, Yang Shen, Yongmei Zhu, Saijuan Chen

Journal Article

Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed

Yinjun Lou, Yafang Ma, Chenyin Li, Sansan Suo, Hongyan Tong, Wenbin Qian, Wenyuan Mai, Haitao Meng, Wenjuan Yu, Liping Mao, Juyin Wei, Weilei Xu, Jie Jin

Journal Article

Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving

Xiaojun Huang, Qian Jiang, Jianda Hu, Jianyong Li, Jie Jin, Fanyi Meng, Zhixiang Shen, Ting Liu, Depei Wu, Jianmin Wang, Jianxiang Wang

Journal Article

A ruptured recurrent small bowel gastrointestinal stromal tumour causing hemoperitoneum

Eric C.H. Lai,Kam Man Chung,Stephanie H.Y. Lau,Wan Yee Lau

Journal Article

Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase

Lanping Xu,Huanling Zhu,Jianda Hu,Depei Wu,Hao Jiang,Qian Jiang,Xiaojun Huang

Journal Article